Loading
A phase 3 trial of Golcadomide, Rituximab, Lenalidomide in follicular lymphoma, run by Celgene, now recruiting.
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) is a phase 3 interventional study registered as NCT06911502 by Celgene, with 400 participants planned, started 2025-07-28 and due to reach its primary completion in 2028-04-24. Interventions recorded: Golcadomide, Rituximab, Lenalidomide, Cyclophosphamide, Doxorubicin. Conditions listed: Follicular Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Golcadomide, PROTACs & molecular glues (targeted protein degradation), Vincristine, Rituximab.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Vincristine, Rituximab.
Shares Lenalidomide, Vincristine, Rituximab, Follicular lymphoma.
Shares Vincristine, Rituximab, Follicular lymphoma, Doxorubicin.
Shares Vincristine, Rituximab, Follicular lymphoma, Doxorubicin.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Lenalidomide, Vincristine, Rituximab, Follicular lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/